The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations

References

• Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Molecular Medicine Today 2000;6:157–162.
   PubMedGoogle Scholar
• Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer 1955;9:539–549.
   PubMed Web of Science ®Google Scholar
• Brown JM. Evidence of acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. British Journal of Radiology 1979;52:650–656.
   PubMedGoogle Scholar
• Rofstad EK. Microenvironment-induced cancer metastasis. International Journal of Radiation Biology 2000;76:589–605.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Designs 1998;13:529–539.
   PubMedGoogle Scholar
• Rauth AM, Melo T, Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. International Journal of Radiation Oncology, Biology & Physics 1998;42:755–762.
   Google Scholar
• Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FCD, Telfer BA, Wind NS, Stratford IJ. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Research 2004;64:1396–1402.
   PubMed Web of Science ®Google Scholar
• Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Research 2004;64: 736–742.
   Google Scholar
• Rauth AM, Melo T, Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. International Journal of Radiation Oncology, Biology & Physics 1998;42:755–762.
   Google Scholar
• Hay MP, Pruijn FB, Gamage SA, Liyanage HDS, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. Journal of Medical Chemistry 2004;47: 475–488.
   Google Scholar
• Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacology Reviews 2004;56:53–102.
   Google Scholar
• Nagasawa H, Yamashita M, Mikamo N, Shimamura M, Oka S, Uto Y, Hon H. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. Computational Biochemical Physiology A-Molecualr Integrated Physiology 2002;132:33–40.
   Google Scholar
• Griffin RJ, Okajima K, Ogawa A, Song CW. Radiosensitization of two murine tumours with mild temperature hyperthermia and carbogen breathing. International Journal of Radiation Biology 1999;75:1299–1306.
   PubMed Web of Science ®Google Scholar
• Masunaga S, Ono K, Hon H, Kinashi Y, Suzuki M, Takagaki M, Kasai S, Nagasawa H, Uto Y. Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. International Journal of Hyperthermia 1999;15:7–16.
   Google Scholar
• Masunaga S, Ono K. Significance of the response of quiescent cell populations within solid tumors in cancer therapy. Journal of Radiation Research 2002;43:11–25.
   PubMed Web of Science ®Google Scholar
• Masunaga S, Ono K, Suzuki M, Nishimura Y, Kinashi Y, Takagaki M, Hon H, Nagasawa H, Uto Y, Tsuchiya I, Sadahiro S, Murayame C. Radiosensitization effect by combination with paclitaxel in vivo including the effect on intratumor quiescent cells. International Journal of Radiation Oncology, Biology & Physics 2001;50:1063–1072.
   PubMedGoogle Scholar
• Nishimura Y, Ono K, Hiraoka M, Masunaga S, Jo S, Shibamoto Y, Sasai K, Abe M, Iga K, Ogawa Y. Treatment of murine SCCVII tumors with localized hyperthermia and temperature-sensitive liposomes containing cisplatin. Radiation Research 1990:122:161–167.
   PubMed Web of Science ®Google Scholar
• Seng F, Ley K. Simple synthesis of 3-amino-1,2,4-benzotriazine-1,4-dioxide. Angewandte Chemie International Edition England 1972;11:1009–1010.
   Web of Science ®Google Scholar
• Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology, Biology & Physics 1986;12: 1239–1242.
   Google Scholar
• Ando K, Koike S, Ohira C, Chen YJ, Nojima K, Ando S, Ohbuchi T, Kobayashi N, Shimizu W, Urano M. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. International Journal of Radiation Biology 1999;75:505–512.
   PubMed Web of Science ®Google Scholar
• Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. International Journal of Radiation Oncology, Biology & Physics 1984;10:695–712.
   PubMedGoogle Scholar
• Masunaga S, Ono K, Abe M. The detection and modification of the hypoxic fraction in quiescent cell populations in murine solid tumors. British Journal of Radiology 1993;66:918–926.
   Google Scholar
• Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Japanese Journal of Cancer Research 1996;87:98–104.
   PubMedGoogle Scholar
• Ono K, Masunaga S, Akuta K, Akaboshi M. Middle dose rate irradiation in combination with carbogen inhalation selectively and more markedly increases the response of SCCVII tumors. International Journal of Radiation Oncology, Biology & Physics 1994;29:81–85.
   PubMedGoogle Scholar
• Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology 2004;14:198–206.
   PubMed Web of Science ®Google Scholar
• Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Molecular Cell Biology 2001;21: 1297–1310.
   Google Scholar
• Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Research 2000;60:6788–6793.
   PubMed Web of Science ®Google Scholar
• Roth JA, Swisher SG, Mevn RE. p53 tumor suppressor gene therapy for cancer. Oncology (Huntington) 1999;13: 148–154.
   Google Scholar
• Hammond EM, Done MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. Journal of Biological Chemistry 2003;278:12207–12213.
   Google Scholar
• Lowe SW, Ruley HE, Lacks T, Housman DE. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–967.
   PubMed Web of Science ®Google Scholar
• Masunaga S, Ono K, Takahashi A, Ohnishi K, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Nagasawa H, Uto Y, Hon H. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status. Cancer Science 2003;94: 125–133.
   Google Scholar
• Masunaga S, Takahashi A, Ohnishi K, Ohnishi T, Nagata K, Suzuki M, Kinashi Y, Ono K. Effects of mild temperature hyperthermia and p53 status on the size of hypoxic fractions in solid tumors, with reference to the effect in intratumor quiescent cell populations. International Journal of Radiation Oncology, Biology & Physics 2004;60:570–577.
   PubMed Web of Science ®Google Scholar